{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Dinaciclib",
  "nciThesaurus": {
    "casRegistry": "779353-01-4",
    "chebiId": "",
    "chemicalFormula": "C21H28N6O2",
    "definition": "A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis.",
    "fdaUniiCode": "4V8ECV0NBQ",
    "identifier": "C78854",
    "preferredName": "Dinaciclib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C2185"
    ],
    "synonyms": [
      "2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5- a]pyrimidin-5-yl]-, (2S)-",
      "CDK Inhibitor SCH 727965",
      "CDK inhibitor SCH 727965",
      "DINACICLIB",
      "Dinaciclib",
      "MK-7965",
      "SCH 727965",
      "dinaciclib"
    ]
  }
}